期刊
PHARMACEUTICS
卷 13, 期 2, 页码 -出版社
MDPI
DOI: 10.3390/pharmaceutics13020201
关键词
microemulsion; nose to brain; drug delivery; blood– brain barrier
资金
- European Union [778051]
- Ministry of Science and Higher Education of Poland [3899/H2020/2018/2]
- Marie Curie Actions (MSCA) [778051] Funding Source: Marie Curie Actions (MSCA)
Nose-to-brain drug delivery has gained significant attention as a route to deliver drugs directly to the central nervous system, bypassing the blood-brain barrier. Challenges include the small volume of the nasal cavity and limited drug absorption, which can be addressed by using drug carriers to enhance delivery efficiency.
Nose-to-brain drug delivery has recently attracted enormous attention as an alternative to other delivery routes, including the most popular oral one. Due to the unique anatomical features of the nasal cavity, drugs administered intranasally can be delivered directly to the central nervous system. The most important advantage of this approach is the ability to avoid the blood-brain barrier surrounding the brain and blocking the entry of exogenous substances to the central nervous system. Moreover, selective brain targeting could possibly avoid peripheral side effects of pharmacotherapy. The challenges associated with nose-to-brain drug delivery are mostly due to the small volume of the nasal cavity and insufficient drug absorption from nasal mucosa. These issues could be minimized by using a properly designed drug carrier. Microemulsions as potential drug delivery systems offer good solubilizing properties and the ability to enhance drug permeation through biological membranes. The aim of this review is to summarize the current status of the research focused on microemulsion-based systems for nose-to-brain delivery with special attention to the most extensively investigated neurological and psychiatric conditions, such as neurodegenerative diseases, epilepsy, and schizophrenia.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据